Prognostic biomarkers for pediatric Crohn’s disease


Andrés Hurtado-Loreanzo, Ph.D. Vice President, Translational Research at Crohn’s & Colitis Foundation


Get access to this webinar, as well as the rest of our categorized library of more than 20 high-quality scientific webinars featuring presentations by leading researchers in their respective fields.

View webinar

Crohn’s disease (CD) is a heterogenous inflammatory bowel disease defined by a chronic inflammation of the gastrointestinal (GI) tract. Unfortunately, the early prediction of disease course and response to treatment is lacking. To address this unmet need, Dr. Hurtado-Lorenzo describes a longitudinal and multiomics study with the largest cohort of pediatric CD patients (n = 913) to date. Using invasive biopsy samples, gene expression analyses were first performed.

Thirteen (13)-gene signatures of disease complications (i.e., fibrosis, fistulas) or response to anti-TNFα treatment were discovered with areas under the curve (AUCs) of 0.93 or 0.91, respectively. Using minimally invasive plasma samples, proteins were screened with the Olink® Target platform. Fourteen (14) proteins predictive of disease complications were identified with an AUC of 0.84. Three (3) proteins were also identified that classified responders and non-responders to treatment with an AUC of 0.90. Moreover, the inter- and intra- coefficient of variations (CVs) between Olink runs was 7%, on average. A custom Olink assay with these 17 proteins is currently being produced for further validation.

This multiomics study revealed biological predictors of disease complications with high accuracy at the time of diagnosis, which may improve the quality of life for children with Crohn’s disease. The Olink platform is also being used in a separate adult CD study to select which patients should be treated with anti-fibrotic drugs.

The webinar covers the following points:

  • Biomarker discovery was performed using plasma and the Olink® Target platform
  • 14 prognostic biomarkers of disease complications were identified with an area under the curve (AUC) of 0.84
  • 3 predictive biomarkers of patient response to anti-TNFα therapy were identified with an AUC of 0.90